Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Visiting Professor



j.stebbing Website CV




ICTEM buildingHammersmith Campus





Justin Stebbing, Professor of Cancer Medicine and Oncology, has specialised in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Professor Stebbing’s original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009.

Professor Stebbing has published over 650 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences. His focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells and cell free DNA. His laboratory work is concentrated on new druggable target discovery and gene regulation examining the role of non-coding RNAs in stem cells. Action Against Cancer logoThe charity Action Against Cancer has been set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.

He is a Fellow of the Royal College of Physicians and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. He chaired the World Vaccine Congress and the Irish Cancer Society oversight committee and has sat on editorial boards of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology; he was awarded the Silvia Lawler prize in 2015. Justin's team published in Nature Medicine the discovery of a new cancer-causing gene which we have now implicated in breast, gastro-intestinal, lung and other solid tumours. The National Institute for Health Research (NIHR) awarded Justin Stebbing its first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. The focus of this is understanding why some patients with cancer relapse, and developing a program to reverse this and prevent it. With the excellent research record we have at Imperial College London and clinical expertise from Imperial College Healthcare NHS Trust, we believe we are ideally placed to achieve this.

He has aimed to link the bench to the bedside and vice versa in a wide number of translational research studies including immunotherapy trials and recent biosimilar studies which aim to make expensive cancer drugs more broadly available in the developing world.

In 2016 Justin was internationally recognised with his appointment as Editor-in-Chief of Oncogene (Springer Nature's foremost cancer journal) and election to the American Society for Clinical Investigation.

Amidst the pandemic, Justin has led broad international collaborations to advance COVID-19 research and his discoveries on baricitinib linking the computer-bench-bedside have led to phase 3 trials and an FDA approval in record timelines.

In March 2022 he resigned from his permanent position at Imperial College and was appointed a Visiting Professor of Cancer Medicine. He still has an active translational research program here.

January 2022 World Health Organization strongly recommends baricitinib

A living WHO guideline on drugs for covid-19

JAK Inhibitors — More Than Just Glucocorticoids

Summary of Justin's Covid-19 work 

Summary (PDF)

FDA approves baricitinib to treat COVID-19:

Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19

New baricitinib data published in Science Advances by a huge team, linking the computer-laboratory-clinic:

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

COVID-19 survival among elderly patients could be improved by arthritis drug

Latest data on LMTK3 including a new molecule to block it published next to our COVID work in Science Advances:

The structure-function relationship of oncogenic LMTK3

Meta-analysis on cancer and COVID-19 published by Justin's team in the JNCI

Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis

Cancer patients at increased risk of severe outcomes from COVID-19


Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir


Characterisation of the cytokine storm tells us who will become sick in advance These changes are improved by Baricitinib

Data on baricitinib linking AI, the clinic and laboratory published:

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

Can artificial intelligence identify effective COVID‐19 therapies?
By David Sinclair (author of Lifespan), regarding our work

Baricitinib for covid-19 taken into large US randomised-controlled trials

Potential treatment for COVID-19 identified by BenevolentAI using artificial intelligence enters randomised clinical trial (April 11, 2020)

Lilly Begins Clinical Testing of Therapies for COVID-19 (April 10, 2020)

Lilly begins its own placebo-controlled randomised trial referencing our COVID-19
(June 15, 2020)

Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients (June 15, 2020)


Baricitinib for COVID-19: a suitable treatment? – Authors' reply (pdf)

COVID-19: combining antiviral and anti-inflammatory treatments

Baricitinib as a potential treatment for CoVID-19 acute respiratory disease

Professor Stebbing discusses the role of biosimilars in the Journal of Clinical Oncology, increasing access to high value drugs

Read more in the Journal of Clinical Oncology

Sir Michael Parkinson meets Professor Justin Stebbing

Sir Michael Parkinson meets Professor Justin Stebbing from Action Against Cancer on Vimeo.

Justin gives a Talk with Pulitzer Prize Winner (For The Emperor Of All Maladies), Dr Siddhartha Mukherjee

Prof Stebbing gives a talk with Pulitzer Prize-winning author Siddhartha Mukherjee who wrote "The Emperor of Maladies"

Selected Publications

Journal Articles

Lenz H-J, Richardson P, Stebbing J, 2021, The Emergence of Baricitinib: A Story of Tortoises Versus Hares, Clinical Infectious Diseases, Vol:72, ISSN:1058-4838, Pages:1251-1252

Magbanua MJM, Hendrix LH, Hyslop T, et al., 2021, Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy, Journal of the National Cancer Institute, Vol:113, ISSN:0027-8874, Pages:443-452

Carli G, Cecchi L, Stebbing J, et al., 2021, Is asthma protective against COVID-19?, Allergy, Vol:76, ISSN:0105-4538, Pages:866-868

Zagorac S, de Giorgio A, Dabrowska A, et al., 2021, SCIRT lncRNA restrains tumorigenesis by opposing transcriptional programs of tumor-initiating cells., Cancer Research, Vol:81, ISSN:0008-5472, Pages:580-593

Williams J, Stebbing J, 2021, COVID-19 and the risk to cancer patients in China., International Journal of Cancer, Vol:148, ISSN:0020-7136, Pages:265-266

Stebbing J, Nievas GS, Falcone M, et al., 2021, JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Science Advances, Vol:7, ISSN:2375-2548, Pages:1-15

Sims JT, Krishnan V, Chang C-Y, et al., 2021, Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19, Journal of Allergy and Clinical Immunology, Vol:147, ISSN:0091-6749, Pages:107-111

Ottaviani S, Stebbing J, 2020, What is the best drug to treat COVID-19? The need for randomized controlled trials, Medicine, Vol:1, ISSN:1357-3039, Pages:9-10

Zhang H, Han H, He T, et al., 2020, Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis, Journal of the National Cancer Institute, Vol:113, ISSN:0027-8874, Pages:371-380

Ditsiou A, Cilibrasi C, Simigdala N, et al., 2020, The structure-function relationship of oncogenic LMTK3, Science Advances, Vol:6, ISSN:2375-2548

Pelisser M, Thompson J, Majra D, et al., 2020, Sports balls as potential SARS-CoV-2 transmission vectors., Public Health in Practice, Vol:1, ISSN:2666-5352, Pages:1-5

Tabassum N, Cereser B, Stebbing J, 2020, A cell-cycle signature classifier for pan-cancer analysis, Oncogene, Vol:39, ISSN:0950-9232, Pages:6041-6042

Cereser B, Tabassum N, Belluz LDB, et al., 2020, Mutational landscapes of normal breast during age and pregnancy determine cancer risk, Biorxiv

Stebbing J, Krishnan V, de Bono S, et al., 2020, Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients, EMBO Molecular Medicine, Vol:12, ISSN:1757-4676, Pages:1-15

Kumleben N, Bhopal R, Czypionka T, et al., 2020, Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers, Public Health, Vol:185, ISSN:0033-3506, Pages:88-90

Peng L, Yang J-S, Stebbing J, 2020, Lessons to Europe from China for cancer treatment during the COVID-19 pandemic, British Journal of Cancer, Vol:123, ISSN:0007-0920, Pages:7-8

Richardson P, Griffin I, Tucker C, et al., 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease (vol 395, pg e30, 2020), The Lancet, Vol:395, ISSN:0140-6736, Pages:1906-1906

Gagliano T, Shah K, Gargani S, et al., 2020, PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression, Journal of Clinical Investigation, Vol:130, ISSN:0021-9738, Pages:3188-3204

Peng L, Zagorac S, Stebbing J, 2020, Managing patients with cancer in the COVID-19 era, European Journal of Cancer, Vol:132, ISSN:0959-8049, Pages:5-7

Smith K, Galazi M, Openshaw MR, et al., 2020, The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer, Clinical Genitourinary Cancer, Vol:18, ISSN:1558-7673, Pages:E217-E223

Richardson PJ, Ottaviani S, Prelle A, et al., 2020, CNS penetration of potential anti-COVID-19 drugs., Journal of Neurology, Vol:267, ISSN:0340-5354, Pages:1880-1882

Stebbing J, Mainwaring PN, Curigliano G, et al., 2020, Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars, Journal of Clinical Oncology, Vol:38, ISSN:0732-183X, Pages:1070-+

Stebbing J, Phelan A, Griffin I, et al., 2020, COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infectious Diseases, Vol:20, ISSN:1473-3099, Pages:400-402

Bhimani J, Ball K, Stebbing J, 2020, Patient-derived xenograft models-the future of personalised cancer treatment, British Journal of Cancer, Vol:122, ISSN:0007-0920, Pages:601-602

Richardson P, Griffin I, Tucker C, et al., 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, The Lancet, Vol:395, ISSN:0140-6736, Pages:E30-E31

Peng L, Qin B-D, Xiao K, et al., 2020, A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy, Oncoimmunology, Vol:9, ISSN:2162-402X

Huang Y, Gu B, Liu C, et al., 2019, Thermosensitive liposome-mediated drug delivery in chemotherapy: mathematical modelling for spatio-temporal drug distribution and model-based optimisation, Pharmaceutics, Vol:11, ISSN:1999-4923

Gagliano T, Shah K, Gargani S, et al., 2019, Global kinome silencing combined with 3D invasion screening of the tumor microenvironment identifies fibroblast-expressed PIK3Cδ involvement in triple-negative breast cancer progression

Fu C, Stebbing J, Esteva FJ, 2019, Clinical development of CT-P6 in HER2 positive breast cancer, Expert Opinion on Biological Therapy, Vol:19, ISSN:1471-2598, Pages:987-992

Esteva FJ, Baranau YV, Baryash V, et al., 2019, Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial, Cancer Chemotherapy and Pharmacology, Vol:84, ISSN:0344-5704, Pages:839-847

Lane R, Simon T, Vintu M, et al., 2019, Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping, Communications Biology, Vol:2

Lane R, Simon T, Vintu M, et al., 2019, Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping., Commun Biol, Vol:2

Ottaviani S, Stebbing J, Frampton AE, et al., 2019, Author Correction: TGF-beta induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression, Nature Communications, Vol:10, ISSN:2041-1723

Stebbing J, Singh Wasan H, 2019, Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making., J Clin Oncol, Vol:37, Pages:1847-1850

Coombes RC, Page K, Salari R, et al., 2019, Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence, Clinical Cancer Research, Vol:25, ISSN:1078-0432, Pages:4255-4263

Cristofanilli M, Pierga J-Y, Reuben J, et al., 2019, The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper, Critical Reviews in Oncology Hematology, Vol:134, ISSN:1040-8428, Pages:39-45

Simon T, Pinioti S, Schellenberger P, et al., 2018, Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma, Molecular Cancer, Vol:17, ISSN:1476-4598

Bidard F-C, Michiels S, Riethdorf S, et al., 2018, Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis, Journal of the National Cancer Institute, Vol:110, ISSN:0027-8874, Pages:560-567

Ottaviani S, Stebbing J, Frampton AE, et al., 2018, TGF-beta induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression, Nature Communications, Vol:9, ISSN:2041-1723

Huang Q, Zhang H, Hai J, et al., 2018, Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials, Oncoimmunology, ISSN:2162-4011

Pannuti A, Filipovic A, Hicks C, et al., 2018, Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors, PLOS One, Vol:13, ISSN:1932-6203

Stebbing J, Shah K, Lit LC, et al., 2018, LMTK3 confers chemo-resistance in breast cancer, Oncogene, Vol:37, ISSN:0950-9232, Pages:3113-3130

Esteva FJ, Stebbing J, Wood-Horrall RN, et al., 2018, A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab, Cancer Chemotherapy and Pharmacology, Vol:81, ISSN:0344-5704, Pages:505-514

Miller G, Stebbing J, 2017, Thirty years of Oncogene, Oncogene, Vol:37, ISSN:0950-9232, Pages:553-554

Stebbing J, Sanders DA, 2017, The importance of being earnest in post-publication review: scientific fraud and the scourges of anonymity and excuses., Oncogene, Vol:37, ISSN:0950-9232, Pages:695-696

Chandrasinghe P, Cereser B, Moorghen M, et al., 2017, Role of SMAD proteins in colitis-associated cancer: from known to the unknown., Oncogene, Vol:37, ISSN:0950-9232, Pages:1-7

Harding V, Stebbing J, 2017, Liquorice: a treatment for all sorts?, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:1155-1155

Stebbing J, Baranau Y, Baryash V, 2017, CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017), Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:E510-E510

Wendler F, Favicchio R, Simon T, et al., 2017, Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention, Oncogene, Vol:36, ISSN:0950-9232, Pages:877-884

Zanini E, Louis LS, Antony J, et al., 2017, The tumor suppressor protein OPCML potentiates anti-EGFR and anti-HER2 targeted therapy in HER2-positive ovarian and breast cancer., Molecular Cancer Therapeutics, Vol:16, ISSN:1535-7163, Pages:2246-2256

Stebbing J, Baranau Y, Baryash V, 2017, CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017), Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:E433-E433

Craddock C, Cathcart P, Stebbing J, 2017, Chilli-too hot to handle?, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:1005-1005

Stebbing J, Baranau Y, Baryash V, et al., 2017, CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:917-928

Cathcart P, Craddock C, Stebbing J, 2017, Fasting: starving cancer., Lancet Oncology, Vol:18, ISSN:1474-5488, Pages:431-431

Esteva FJ, Lee SJ, Stebbing J, et al., 2017, Phase I clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6, Breast, Vol:32, ISSN:0960-9776, Pages:S68-S69

Meijer LL, Frampton AE, Garajova I, et al., 2017, Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma, The Lancet, Vol:389, ISSN:0140-6736, Pages:68-68

Boulianne B, Robinson ME, May PC, et al., 2017, Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B-cell precursors, Cell Reports, Vol:18, ISSN:2211-1247, Pages:1687-1698

Askari A, Nachiappan S, Currie A, et al., 2017, The relationship between ethnicity, social deprivation and late presentation of colorectal cancerle, Cancer Epidemiology, Vol:47, ISSN:1877-7821, Pages:88-93

Page K, Guttery DS, Fernandez-Garcia D, et al., 2017, Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer, Clinical Chemistry, Vol:63, ISSN:0009-9147, Pages:532-541

Castellano L, Dabrowska A, Pellegrino L, et al., 2017, Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR, Nucleic Acids Research, Vol:45, ISSN:1362-4962, Pages:4401-4412

Balachandran K, Stebbing J, 2016, Turmeric: a spice for life?, Lancet Oncol, Vol:17, Pages:1639-1639

Tree AC, Harding V, Bhangu A, et al., 2016, The need for multidisciplinarity in specialist training to optimize future patient care, Nature Reviews Clinical Oncology, Vol:14, ISSN:1759-4774, Pages:508-517

Nachiappan S, Askari A, Mamidanna R, et al., 2016, Initiation of adjuvant chemotherapy within 8weeks of elective colorectal resection improves overall survival regardless of reoperation, Colorectal Disease, Vol:18, ISSN:1462-8910, Pages:1041-1049


Stebbing J, Baranau Y, Baryash V, et al., 2019, 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC), 44th Congress of the European-Society-for-Medical-Oncology (ESMO), OXFORD UNIV PRESS, Pages:63-+, ISSN:0923-7534

Cereser B, Tabassum N, Carter P, et al., 2018, Study of the mutational landscape of normal and pregnant breast to predict pregnancy-associated breast cancer risk, San Antonio Breast Cancer Symposium 2018

Esteva FJ, Baranau Y, Baryash V, et al., 2017, Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC), 42nd European-Society-for-Medical-Oncology Congress (ESMO), OXFORD UNIV PRESS, ISSN:0923-7534

Stebbing J, Valerievich Y, Baryash BV, et al., 2017, Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC), 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, AMER SOC CLINICAL ONCOLOGY, ISSN:0732-183X

Pinato DJ, Stebbing J, Ishizuka M, et al., 2012, A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI), Elsevier, Pages:1013-1020, ISSN:1600-0641

More Publications